studies completed
0
+
Proteas offers high-end proteomic services with unsurpassed depth of analysis using a proprietary and globally unique platform. At competitive prices we offer a complete solution for targeted and untargeted protein analysis in cells, tissue and plasma from pre-clinical and clinical research studies followed by project-specific statistics and machine learning (ML) | artificial intelligence (AI) enhanced bioinformatics analysis. Our analyses are geared towards novel drug target identification, assessment of drug effects and biomarker discovery. Get in touch and find out how next generation proteomics can power up your research!
Initial meeting with client to discuss project
Proteas sends Service Contract with
Scope of work | Aims
Budget | Project timeline
Client ships samples to Proteas lab
Proteas performs proteomics & ML/AI data analysis with our globally patented platforms
Proteas sends Data Package
Protein Lists | Figures
QA/QC | Raw data files
Follow-up meeting with client to discuss results
Project support for
manuscript | grant submission
Client testimonials
Testimonials
Proteas provided exceptional results on the proteomic profiling of brain tumors. Their patented platform is geared towards early diagnosis and personalized treatment of disease and has great potential in changing medical practice as we know it today. Proteas’ founders, Spiro and Antigoni are global proteomics experts with unparalleled know-how and scientific curiosity. Working with them has been a pleasure.
A lack of clinical tools that enable identification of high-risk pre-malignant multiple myeloma patients means that the current clinical approach is to only treat these patients when they develop active myeloma. Our collaboration with Dr. Garbis and Dr. Manousopoulou at Proteas has made significant progress in the development of novel blood biomarkers that are predictive of the progression from pre-malignant to active myeloma.
I’ve had the pleasure to work and author articles with Dr. Garbis and Dr. Manousopoulou (a former student of mine) over the years. This work involved using the Plasma Proteomics Technology developed by Dr. Garbis at Proteas. The analytical rigor of this technology stands to transform our understanding of how chronic stress affects human physiology and pathophysiology.
My team and I have had the distinct pleasure to collaborate with Proteas over this past year on multiple studies in the field of neurodegenerative disorders. Thanks to the outstanding proteomics and phosphoproteomics analysis performed by Proteas to a variety of biological specimens we obtained a more in-depth understanding the role of synaptic proteins in complex brain disorders. I have had nothing but positive experience working with Dr. Manousopoulou and Dr. Garbis at Proteas and recommend their work without any reservation.
Working with the founders of Proteas is an absolute joy. They are super-smart, exceptionally creative, and extraordinarily thorough. They will work closely with you to understand what you’re doing and what you’re trying to figure out, then help design the best and most efficient experiment to get you the answer. They will make whatever project you bring them better.
I worked with Proteas on the proteomic profiling of HIV infected cells, both for single cell analysis and bulk cell analysis. They can work with minimal protein amounts and provide outstanding results and extensive follow-up support for manuscript and grant submission. We have a active, on-going collaboration and have submitted multiple NIH grants together. The founders of Proteas are amazing scientists and global leaders in the field of proteomics. Working with Proteas was an excellent experience and I highly recommend them.
